


Index



A

- Abciximab, 68, 70
- Absorption, 5
- Acetaminophen, 171–174, 179, 198
 - hepatotoxicity, 173, 174
 - pharmacokinetics, 172–173, 174
- Acetylcholine, 8
- Acetylsalicylic acid, 64, 69
- Acute leukemia, 116
- Acyclovir, 30–31
- Adjusted body weight, 3, 4
 - creatinine clearance, 11
- Adjuvant analgesics, 176
- Age-based dosing, 141
- Alcohol consumption, 198, 199
- Alemtuzumab, 131
- Alfentanil, 178, 179
- Alkylating agents, 117–119, 130
- Alprazolam, 88
- Alteplase (rt-PA), 63, 69
- Amikacin, 19
- Aminoglycoside, 5, 19–20
 - concentration-dependent, 15, 16
 - dosing, 2–3, 33
 - pediatric patient and, 145, 146, 148, 149
 - weight to use for, 36
- Aminopenicillins, 17
- Aminophylline, 90, 91
- Amiodarone, 83, 84, 85
- Amitriptyline, 179, 192
- Amoxicillin, 17, 184, 187
- Amphotericin, 16
- Amphotericin B, 29–30
- Ampicillin, 17, 198
- Ampicillin/sulbactam, 17
- Analgesics, 171–181, 195–196, 199
 - pediatric, 141–142, 149
- Anidulafungin, 29
- Anthracyclines, 124–125, 127, 130
- Antiarrhythmics, 83–85, 94
- Antibiotics, 16–26, 36–37, 184, 186–187, 199
- Antibody reduction therapy, 163
- Antibody-mediated rejection, 164
- Anticoagulant, dosing, 69–70
- Anticoagulants, 45–46
 - dosing, 69–70
 - pediatric, 143–144, 149
- Anticonvulsants, 9
- Antidepressants, 192
- Antiepileptic agents, 97–107
- Antifungal agents, 16, 26–30, 37
- Antihypertensive agents, 79–82
- Antimetabolite agents, 122–123, 130
- Antimicrobial agents
 - dosing, 15–16
 - dosing, sample calculations, 33–35
 - pediatric, 145–146, 149
 - summary table, 36–38
- Antimicrotubule agents, 121–122, 130
- Antineoplastic agents, 117–127, 193
 - dosing, 109–137
 - pediatric, 146–147, 149
- Antiplatelet dosing, 64–70
- Antiproliferative agents, 158–160, 165
- Antipsychotic agents, 9
- Antituberculosis agents, 25–26, 37
- Antiviral agents, 16, 30–33, 38, 187–188, 200
- Apixaban, 62, 69
- Area under the curve, 110
- Argatroban, 59, 69
- Arsenic trioxide, 126, 131
- Aspirin, 64, 65, 69, 143
- Atenolol, 79
- Atorvastatin, 10, 193–194, 195, 199
- Atracurium, 86
- Azathioprine, 160
- Azithromycin, 16, 186, 187, 199

Azoles, 26–28, 37

Aztreonam, 18

B

Bariatric surgery, 183–202

medications and, 198

Basiliximab, 156, 162, 165

Belatacept, 162, 165

Benefield, Emily C., 139–151

Benzodiazepines, 8, 87–88, 90

Beta-blockers, 9, 79–81, 94

Beta-lactams, 15, 16–18, 36, 146

Bivalirudin, 59, 69

anticoagulation in PCI, 59

HIT treatment, 59

Bleomycin, 126, 131

Body mass index (BMI), 2, 3

pediatric, 139–140

Body size descriptors, 3

Body surface area (BSA), 2, 141

alternatives, 112–113

determination, 110–112

Breast cancer, 113–114, 117

Brentuximab vedotin, 126, 127, 131

Bronchodilators, 90

Bupropion, 192

Buspirone, 192

Busulfan, 112, 117–118, 130, 147, 148, 149

C

Calcineurin inhibitors, 156–158, 161, 165

Calcium channel blockers, 81–82, 94

Calcium products, 196, 198

Capping doses, 113

Carbamazepine, 97, 99, 102–103, 106

dosing weight, 102–103

Carbapenems, 16, 18, 36

Carboplatin, 119–121, 127, 130

sample calculation, 128–129

Cardiovascular agents, 193–195, 199

Cardiovascular/resuscitation, 143, 149

Carfilzomib, 125, 127, 130

Carmustine, 118, 130

Caspofungin, 28

Cefazolin, 17, 146

Cefdinir, 18

Cefepime, 33

Cefotaxime, 18

Cefoxitin, 17

Ceftaroline, 18

Ceftazidime, 18

Ceftriaxone, 18

Cefuroxime, 18

Celecoxib, 175, 179

Centers for Disease Control and Prevention, 139–140

Cephalosporins, 16, 17–18, 149

Chemotherapy dosing, 113–114, 117

Chloral hydrate, 142

Chronic leukemia, 116

Cidofovir, 32

Cilostazol, 67, 70

Ciprofloxacin, 21

Cisatracurium, 85, 86

Cisplatin, 121, 127, 130

Citalopram, 192

CKD-EPI equation, 7, 8

Clarithromycin, 22

Clearance, 6–8

Clevidipine, 81–82

Clindamycin, 16, 24, 25

Clobazam, 105

Clofarabine, 130

Clonazepam, 192

Clopidogrel, 65, 66, 67, 70

Clozapine, 192

Cockcroft-Gault equation, 7, 8, 34–35, 120, 127

Colistin, 23–24

Colorectal cancer, 114, 117

Concentration-dependent activity, 15, 16

Cook, Aaron M., 15–43

Corticosteroids, 91–92, 95, 162

Costimulatory blockade, 162

Creatinine clearance, 6–7

estimation, 10–11

equations, 8

Critical care, 77–96

Critically ill drugs, 93–94

Cyclophosphamide, 118, 130

Cyclosporine, 5, 156–157, 158, 198

Cyclosporine-corticosteroid studies, 161

Cytarabine, 122, 130, 147

Cytomegalovirus, 31–32, 38

D

Dabigatran, 61, 62, 69

Dalbavancin, 20

Dalteparin, 69

VTE therapeutic dosing, 53

Daptomycin, 16, 20–21, 36

Darunavir, 187, 200

Daunorubicin, 124, 130

Depolarizing agents, 85–86, 87

Dexmedetomidine, 89, 90

Diabetic foot infection case, 34–35

Diazepam, 5, 88, 192

Didanosine, 188

Digoxin, 83–84, 194, 195, 198, 199

Dihydropyridines, 81–82

Diltiazem, 81

Distribution, 5–6

Docetaxel, 121, 130

Dofetilide, 84

Doripenem, 18

Dose capping, 163

Doxorubicin, 124, 130, 146–147, 149

Doxycycline, 23

Drug dosing, weight based, 2

Duloxetine, 190, 192, 199

E

Echinocandins, 16, 28–29, 37

Edoxaban, 62, 69

Efavirenz, 188

Elder, Stacy, 45–74

Emtricitabine, 187, 188, 200

Endocrine agents, 193–195, 199

End-organ function, 110

Enoxaparin, 5, 49–50, 51, 52, 57, 69
Matisse dosing trials, 57
pediatric, 143, 144, 149
VTE therapeutic studies, 53–55, 56

Epirubicin, 124, 130

Eptifibatide, 67, 68, 70

Ertapenem, 18

Erythromycin, 22, 186, 187, 199

Eslicarbazepine acetate, 105

Esmolol, 80

Ethambutol, 25, 198

Ethosuximide, 105, 198

Etoposide, 123, 130, 147

Everolimus, 161, 162, 165

Excretion, 6–7

Extravasation, 78

Ezogabine, 105

F

Felbamate, 105

Fentanyl, 177–178, 179

pediatric, 141–142

Fibrinolytics, 62–64, 69
 Filgrastim, 131
 Fixed-dose chemotherapy, 113
 Flannery, Alexander H., 15–43
 Fluconazole, 26, 27, 28
 Flucytosine, 30
 Fludarabine, 122, 130
 Fluoroquinolones, 16, 21, 36
 Fluorouracil, 122, 130
 Fluoxetine, 192
 Fondaparinux, 57–59, 69
 Matisse dosing trials, 57
 VTE prophylaxis, 57–58
 Foscarnet, 31, 32
 Fosfomycin, 25
 Fosphenytoin, 98, 100
 Free-fat mass, 3, 4
 Furosemide, 194, 195, 199

G

Gabapentin, 105
 Ganciclovir, 31–32
 Gastrointestinal therapy, 196, 199
 Gemcitabine, 123, 130
 Genetic animal model, 6
 Gengraf, 157
 Gentamicin, 7, 19, 36, 145
 Glomerular filtration rate, 6–7
 Glucocorticoids, 9
 Glycopeptides, 20, 36
 GP IIb/IIIa inhibitors, 67–68, 70
 Granulocyte-colony stimulating factors, 126–127
 Gynecological cancer, 114, 117

H

Haloperidol, 191, 192, 200
 Healthy living, 9
 Hematologic cancers, 115–117
 Heparin, 69
 Herpes simplex virus, 31, 38
 Histamine-2 receptor antagonists, 92, 95
 Hydralazine, 82
 Hydrochlorothiazide, 198
 Hydroxychloroquine, 188, 190, 199
 Hydroxyzine, 142

I

Ibuprofen, 174, 175, 179
 Ibutilide, 84
 Idarubicin, 125, 130

Ideal body weight (IBW), 2, 3, 4
 creatinine clearance, 10
 pediatric, 140
 Ifosfamide, 118–119, 130
 Imatinib, 125, 130, 193, 200
 Imipenem, 18
 Immunomodulators, 188–190, 199
 Immunosuppressants, 188–190, 199
 Immunosuppression, 153–170
 medication dosing, 165
 Induction agents, 165
 Influenza, 32–33, 38
 Inotropes, 78–79
 Insulin glargine, 9, 10
 Insulin resistance, 8–9
 Intensive care unit
 complications risk, 78
 informatics challenges, 78
 pharmacokinetic considerations, 77–78

Intravenous direct thrombin inhibitors, 59–60
 Intravenous immunoglobulin, 162–164, 165
 weight-based dosing, 163
 Irinotecan, 123, 130
 Iron products, 196–197, 198
 Isoniazid, 198
 Itraconazole, 27
 Ixabepilone, 121, 130

K

Ketorolac, 174–175, 179

L

Labetalol, 79
 Lacosamide, 97, 104, 106
 dosing weight, 104
 Lamivudine, 187, 188, 200
 Lamotrigine, 105, 191, 192
 Lean body weight (LBW), 2, 3, 4
 creatinine clearance, 10
 Length-based tape, 143
 Levetiracetam, 97, 103, 104, 106
 dosing weight, 103–104
 Levofloxacin, 21
 renal dose adjustment, 10
 Levothyroxine, 194, 195, 198, 199
 Lidocaine, 84, 85
 Lifestyle changes, 9
 Linezolid, 16, 22, 186, 199
 Liraglutide, 9
 Lithium, 191, 192, 200

L-norgestrel, 198
 Loading doses, 5
 Lorazepam, 88, 192
 Lorcaserin, 9
 Low molecular weight heparin, 46, 47, 49, 69
 ACS therapeutic dosing, 56–57
 bariatric surgery, 50–51, 52
 dosing studies, 49–51, 53
 medical patients, 49, 51
 nonbariatric surgery/trauma patients, 49–50, 51
 therapeutic dosing, 52–56
 VTE prophylaxis dosing, 47, 49
 VTE therapeutic dosing, 52
 Lung cancer, 115, 117
 Lymphoma, 116–117

M

Macrolides, 22–23, 36
 Mammalian target of rapamycin inhibitors, 161–162
 Mardis, B. Andrew, 153–170
 Mardis, Caitlin R., 153–170
 Martin, Craig A., 15–43
 Matisse medication dosing trials, 57
 Matzke nomogram for vancomycin, 35
 Mechlorethamine, 119, 130
 Medication dosing, 4–5
 Melphalan, 112, 119, 130
 Meperidine, 142
 Mercaptopurine, 146, 149
 Meropenem, 18
 Metabolic syndrome, 9
 Metabolism, 6
 Metformin, 194–195, 199
 Methotrexate, 123, 127, 130, 189, 190, 199
 pediatric, 147
 Methylphenidate, 192
 Methylprednisolone, 91
 Methylxanthine derivatives, 90–91, 95
 Metoprolol, 80
 Metronidazole, 16
 Metropolitan Life Insurance Company of New York Data, 2
 Micafungin, 28
 Midazolam, 5, 87–88, 191, 199
 Minocycline, 23
 Modification of Diet in Renal Disease (MDRD), 7
 Monobactams, 16, 18, 36

Monoclonal antibodies, 125–126, 127, 131, 155–156
 Morphine, 142, 177, 178, 179, 195–196, 199
 Moxifloxacin, 21, 186, 199
 Multivitamins, 197
 Mycophenolate mofetil, 158–160, 162
 Mycophenolate sodium, 158–160
 Mycophenolic acid, 165, 189, 190, 199

N

Naltrexone/bupropion, 9
 National Health and Nutrition Examination Survey (NHANES), 140
 National Health Center for Statistics, 140
 Nebivolol, 80
 Nelfinavir, 187, 188, 200
 Nemecek, Branden D., 183–202
 Neoral, 156–157
 Neostigmine, 87
 Nesbit, Suzanne Amato, 171–181
 Neurologic medications, 190–192, 199, 200
 Neuromuscular blocker reversal agents, 94
 Neuromuscular blockers, 85–87, 94
 Neuromuscular reversal agents, 87
 Nicardipine, 81, 82
 Nifedipine, 81
 Nitrofurantoin, 187
 Nitroglycerin, 82
 Nondepolarizing agents, 85, 87
 Nondihydropyridines, 81
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 174–175, 179
 Norethisterone, 198
 Nortriptyline, 176, 179
 Nosocomial pneumonia case, 33–34
 Nutrition supplementation, 196–198, 199
 Nutritional animal model, 6

O

Obesity
 pediatric, 139
 prevalence of, 1
 Olanzapine, 192
 Omeprazole, 196, 199
 Oncology, 199, 200
 Opioids, 149, 177–179
 Oral anticoagulants, 60–62, 69

Oral contraceptives, 9
 Oritavancin, 20
 Orlistat, 9
 Oseltamivir, 32–33
 Osteomyelitis, 34
 Ouellette, Jacquelyn F., 139–151
 Overdose, pediatric, 142
 Overweight, pediatrics, 139
 Oxazolidinones, 22–23, 36
 Oxcarbazepine, 105, 192

P

Paclitaxel, 112, 121–122, 130
 Paralytics, pediatric, 141–142, 149
 Paroxetine, 192
 Patient-specific factors, 8–9
 Pediatrics, 139–151
 Pegfilgrastim, 131
 Penicillin G, 17
 Penicillins, 16–17, 198
 Pentostatin, 130
 Peramivir, 33
 Perampanel, 105
 Percent body fat, 2
 Performance status, 110
 Pharmacodynamic changes, 8–9
 Pharmacokinetic/pharmacodynamic (PK/PD) targets, 15–16
 Pharmacokinetics
 absorption, 5
 acetaminophen, 172–173, 174
 distribution, 5–6
 excretion/clearance, 6–8
 ICU patients, 77–78
 metabolism, 6
 obese pediatric patients, 140–141
 sampling, 10
 Phenobarbital, 97, 99, 101–102, 106, 191, 192, 200
 dosing weight, 101–102
 Phentermine, 9
 Phentermine/topiramate, 9
 Phenytoin, 97–89, 100, 106, 191–192, 198, 200
 equations, 98
 loading dose, 98–99, 100
 loading dose calculation, 105–106
 maintenance dosing, 99, 100
 Phosphodiesterase III inhibitor, 67, 70
 Pilch, Nicole A., 153–170
 Piperacillin, 17

Piperacillin/tazobactam, 34
 Platinum analogues, 119–121, 130
 Plerixafor, 127, 131
 Polyclonal antibodies, 155–156
 Polyenes, 29–30, 37
 Polymyxins, 23–24, 37
 Posaconazole, 27, 28
 Prasugrel, 65–66, 70
 Predicted normal weight, 3, 4
 Prednisolone, 91
 Prednisone, 189, 190, 199
 Pregabalin, 105
 Primidone, 105
 Procainamide, 83, 84
 Procarbazine, 119, 130
 Propofol, 88–89, 142, 149
 Propranolol, 5, 79–80
 Propylthiouracil, 198
 Protease-activated receptor 1 inhibitors, 66–67, 70
 Psychiatric medications, 190–192, 199, 200
 P2Y12 inhibitors, 64–66, 70
 Pyrazinamide, 25

Q

Quetelet, Adolphe, 2
 Quetelet index, 2
 Quetiapine, 192

R

Rabbit anti-thymocyte globulin, 155–156, 165
 Raltegravir, 188
 Ranitidine, 92
 Rasburicase, 127, 131
 Remifentanyl, 178, 179
 Resuscitation, 143
 Reteplase, 63, 69
 Rifampin, 25, 198
 Risperidone, 192
 Ritonavir, 188, 200
 Rituximab, 126, 131
 Rivaroxaban, 61–62, 69
 Rocuronium, 85–86
 Roux-en-Y gastric bypass, 184–185
 medication levels post, 200
 pharmacokinetics, 185–198
 pharmacokinetics, post, 199–200
 Rufinamide, 105

S

Salazar-Corcoran equation, 7, 8, 35
 Sandimmune, 156–157
 Sedation, 148
 Sedatives, 87–90, 94
 pediatric, 141–143, 149
 Selective serotonin reuptake inhibitors, 192
 Serotonin and norepinephrine reuptake inhibitors, 192
 Sertraline, 192, 199
 Severely obese, children, 139
 Shank, Brandon R., 1–13, 109–137
 Sirolimus, 161, 162, 165, 189–190, 199
 Sodium nitroprusside, 82
 Solid tumors, 113–115
 Sotalol, 80
 Stavudine, 188
 Stem cell transplantation, 115–116, 117
 Streptomycin, 25
 Subcutaneous Xa inhibitor, 57–59
 Succinylcholine, 85, 87, 142, 149
 Sufentanil, 178, 179
 Sulfamethoxazole/trimethoprim, 25
 Sulfonylureas, 9
 Sunitinib, 125, 130

T

Tacrolimus, 157–158, 160, 165, 190, 198, 199
 Tamoxifen, 193, 200
 Targeted therapies, 125, 130
 Taxanes, 127
 Tedizolid, 22
 Teicoplanin, 20
 Temozolomide, 193, 199
 Tenecteplase, 63, 69
 Teniposide, 147
 Tenofovir, 188, 200
 Tetracyclines, 16, 22–23, 37
 Thalidomide, 125, 130
 Theophylline, 90, 91
 Thiamine, 197, 198
 Thiazolidinedione, 9
 Thiopental, 89, 90
 Thiotepa, 119, 130
 Thymoglobulin, 155–156
 Ticagrelor, 66, 70
 Ticarcillin, 17
 Ticlopidine, 64, 70
 Tigecycline, 23

Time-dependent activity, 15, 16

Tinzaparin, 69
 VTE therapeutic dosing studies, 55
 Tirofiban, 68, 70
 Tobramycin, 19, 33, 145
 Topiramate, 105
 Topoisomerase inhibitors, 123–124, 130
 Topotecan, 124, 130
 Total body weight (TBW), 2, 4
 creatinine clearance, 11
 Transplantation immunosuppression, 153–155
 Trazodone, 192
 Treatment intent, 110
 Triazoles, 16
 Tricyclic antidepressants, 9, 176–177
 24-hour creatinine clearance, 7, 8

U

Underdose, pediatric, 142–143
 Unfractionated heparin, 46–47, 69
 bariatric surgery dosing, 46–47
 dosing studies, 48
 Matisse dosing trials, 57
 pediatric, 143, 144, 149
 therapeutic dosing, 47
 VTE prophylaxis dosing, 46

V

Valganciclovir, 31, 32
 Valproic acid, 97, 99, 100–101, 106
 dosing weight, 100
 Vancomycin, 16, 20–21, 22, 34, 35
 pediatric, 145–146, 148, 149
 Vasodilators, 82, 94
 Vasopressors, 78–79
 Vecuronium, 85, 86, 87
 Venlafaxine, 176, 179, 192
 Verapamil, 81
 Vigabatrin, 105
 Vinca alkaloids, 127
 Vincristine, 113, 122, 130, 127
 Viral infections, post-transplant, 164
 Vitamin B₁₂, 197, 198
 Vitamin D, 197, 198, 199
 Vitamin supplementation, 196–198, 199
 Vorapaxar, 66–67, 70
 Voriconazole, 26–27, 28

W

Waldfoegel, Julie, 171–181
 Warfarin, 60–61, 62, 69
 pediatric, 143, 144, 149
 Weight
 assessment, 110
 measures of, 2–4
 Weight-based dosing, 141
 Weight-loss medications, 9–10
 World Health Organization, 2, 139–140

Z

Zidovudine, 188, 200
 Zimmerman, David E., 77–96, 97–107
 Ziprasidone, 192
 Zolpidem, 192
 Zonisamide, 105

Notes

Notes

Notes
